| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
BLADDER CANCER, FISH (UROVYSION)
MessageSend to LabCorp. Inform patient of strict Monday-Thursday collection instructions below. Must ship out same day as collection before 1500 EST.
Kits are found in processing in a blue box marked as Dianon pathology - TCC Monitoring Kit
Kits are found in processing in a blue box marked as Dianon pathology - TCC Monitoring Kit
Test Code
LAB775
Alias/See Also
LAB775
LabCorp TC: 130080
UroVysion, FISH
Urothelial Carcinoma, FISH
LabCorp TC: 130080
UroVysion, FISH
Urothelial Carcinoma, FISH
CPT Codes
88120
Preferred Specimen
50 mL Clean Catch Urine
Must be transfered to UroVision kit (TCC Monitoring Kit) for shipment.
Must be transfered to UroVision kit (TCC Monitoring Kit) for shipment.
Minimum Volume
33 mL
Instructions
Step 1: Use the large, open cup in the kit to collect the urine specimen. First void of the day is preferred. Ensure that the urine specimen reaches the minimum fill line of 33 mL. Step 2: Slowly pour urine into the smaller container to the maximum fill line of 90 mL. Step 3: Tighten the lid until you hear a click in order to prevent leakage.
Transport Container
TCC Monitoring kit (PeopleSoft item N° 44921). Other containers that are accepted, but not recommended: PreservCyt® vial, Cytology Special Studies Kit (PeopleSoft item N° 3203), or sterile urine container with Carbowax® fixative (two parts urine; one part fixative).
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated
Specimens should be received at the reference laboratory within 72 hours post collection for optimal testing.
Suggested collections should occur Monday throughThursday.
Specimens should be received at the reference laboratory within 72 hours post collection for optimal testing.
Suggested collections should occur Monday throughThursday.
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Incorrect fixative; significant contamination with blood obscuring bacterial overgrowth; inadequate specimen cellularity.
Methodology
Fluorescence in situ hybridization (including diagnostic interpretation by MD pathologist).
Report Available
4-5 days
Limitations
Positive FISH results in the absence of other signs or symptoms of bladder cancer recurrent may be evidence of other urinary-tract-related cancers (eg, ureter, urethra, renal, and/or prostate in males), and further patient follow-up may be helpful. Negative FISH results in the presence of other signs and symptoms of bladder cancer recurrence may need to be regarded as suspicious false-negative results; repeat testing may be indicated. Although the assay was designed to detect chromsome changes associated with most bladder cancers, there are some bladder cancers whose genetic changes are not targeted by this test.
Clinical Significance
The assay is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from subjects with transitional cell carcinoma of the bladder. This assay does not detect other chromosomal or genetic alterations. Results are intended for use as a noninvasive method of monitoring for tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer. The clinical interpretation of test results should be evaluated within the context of the patient's medical history and other diagnostic laboratory test results.
Performing Laboratory
LabCorp